Phase 1 Myeloma Trial, Recruiting (NCT04162353)

Phase 1 Myeloma Trial, Recruiting NCT04162353 Sponsor: iCell Gene Therapeutics Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT04162353 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be willing to participate and have signed a consent form agreeing to take part in the research
Your diagnosis must be based on the World Health Organization (WHO) 2008 guidelines (confirm with trial site)
You must have already tried all standard treatment options available for your condition
You must have stopped taking immune-suppressing medications or steroid medications for more than 1 week before joining
If you are female, you must not be pregnant during the study

Who may not be able to join:

You are not willing to give your consent to take part in the treatment
You have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
A potentially curative treatment is available to you, such as chemotherapy or a stem cell/bone marrow transplant
You have previously been treated with specific types of targeted therapy drugs known as BCMAxCD3 or CD19xCD3 bispecific agents (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hongyu Zhang, MD/PhD, Peking University Shenzhen Hospital, China

Phone: 6315386218

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04162353

Sponsor: iCell Gene Therapeutics

Phase: Phase 1

Status: Recruiting

Condition: Myeloma

Trial contact: 6315386218

More information: https://clinicaltrials.gov/study/NCT04162353

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be willing to participate and have signed a consent form agreeing to take part in the research
Your diagnosis must be based on the World Health Organization (WHO) 2008 guidelines (confirm with trial site)
You must have already tried all standard treatment options available for your condition
You must have stopped taking immune-suppressing medications or steroid medications for more than 1 week before joining
If you are female, you must not be pregnant during the study

Who may not be able to join:

You are not willing to give your consent to take part in the treatment
You have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
A potentially curative treatment is available to you, such as chemotherapy or a stem cell/bone marrow transplant
You have previously been treated with specific types of targeted therapy drugs known as BCMAxCD3 or CD19xCD3 bispecific agents (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

iCell Gene Therapeutics

Registry

ClinicalTrials.gov

Start date

1 July 2019

Est. completion

1 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of adverse events after BCMA-CD19 cCAR T cells infusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov